Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and market opportunity

• Focused on developing novel oral drugs with biologics-like activity, targeting undrugged pathways validated by injectable biologics to revolutionize immunology.

• Emphasis on immunology, aiming to transform treatment for immune-inflammatory diseases and expand access for 160M patients, with only 3% currently accessing advanced therapies.

• Oral degraders offer biologics-like activity, aiming to transform treatment paradigms and expand access, with plans to build a fully integrated global company.

• Raised nearly $1.6 billion in the past year, securing funding through at least 2029 to advance multiple programs to phase 2 and 3.

• Plans to initiate multiple phase 3 campaigns in parallel for various indications using selected doses from phase 2b studies.

Pipeline progress and clinical milestones

• Pipeline includes KT-621 (STAT6 degrader), KT-579 (IRF5 degrader), and collaborations on IRAK4 and CDK2 programs with Gilead and Sanofi.

• KT-621, a first-in-class oral STAT6 degrader, showed positive Phase 1 and 1b results in 2025 and enabled Phase 2b trials in AD and asthma.

• KT-579, a first-in-class oral IRF5 degrader, completed IND-enabling studies and is set for Phase 1 trials in 2026.

• Collaborations with major pharma partners support further innovation and pipeline expansion.

• Ongoing and upcoming trials include BROADEN2 Phase 2b in AD (data by mid-2027) and BREADTH Phase 2b in eosinophilic asthma (data late-2027).

Clinical data and patient impact

• KT-621 demonstrated robust pathway blockade of IL-4 and IL-13, deep STAT6 degradation (>95%) in blood and skin, and robust efficacy in AD and asthma models.

• Phase 1b data in AD patients showed significant reductions in key biomarkers (TARC, IgE, IL-31, FeNO) and clinical endpoints, including itch, sleeplessness, EASI, and SCORAD.

• KT-621 efficacy was consistent across disease severity and prior biologic exposure, supporting its potential as a first-line therapy.

• KT-621 outperformed dupilumab in FeNO reduction for AD patients with comorbid asthma.

• KT-621 positioned as a drug for all patients with type 2 diseases, including children and adolescents.